📊 BCRX Key Takeaways
Is Biocryst Pharmaceuticals Inc. (BCRX) a Good Investment?
BioCryst demonstrates exceptional revenue growth (+94.1% YoY) and strong profitability metrics (39% operating margin, 30.2% net margin) with robust free cash flow generation ($344.9M). However, the negative stockholders' equity of -$119.2M represents a critical balance sheet deterioration that must be resolved, creating meaningful financial risk despite operational strength.
BioCryst Pharmaceuticals shows a sharp fundamental inflection, with revenue up 94.1% YoY and net income up 396.9% YoY, while converting that growth into strong operating margins and substantial free cash flow. The business now appears materially more self-funding, but negative equity and a liability-heavy balance sheet still warrant some caution despite strong liquidity.
Why Buy Biocryst Pharmaceuticals Inc. Stock? BCRX Key Strengths
- Exceptional revenue growth of 94.1% year-over-year indicating strong market demand
- Impressive net income growth of 396.9% with net margin of 30.2% showing operational leverage
- Strong free cash flow generation at $344.9M (39.4% FCF margin) providing financial flexibility
- Healthy liquidity position with current ratio of 2.06x and quick ratio of 2.03x
- Robust operating cash flow of $347.4M with minimal capital expenditure requirements
- Revenue growth is exceptionally strong at 94.1% YoY, indicating major commercial momentum
- Profitability has improved meaningfully, with 39.0% operating margin and 30.2% net margin
- Cash generation is high quality, with $347.37M operating cash flow and $344.90M free cash flow
BCRX Stock Risks: Biocryst Pharmaceuticals Inc. Investment Risks
- Critical balance sheet weakness with negative stockholders' equity of -$119.2M indicating liabilities exceed assets by $119.2M
- Total liabilities of $633.3M exceed total assets of $514.2M, creating solvency concerns
- Significant insider trading activity with 10 Form 4 filings in last 90 days warrants monitoring for insider confidence signals
- Negative equity makes traditional leverage metrics meaningless and limits financing flexibility
- Sustainability of 94% revenue growth rates uncertain; margin compression risk if growth moderates
- Stockholders equity is negative, which signals accumulated balance sheet strain despite current profitability
- Total liabilities exceed total assets, limiting financial flexibility if operating performance weakens
- Recent results may be difficult to sustain if growth normalizes after a breakout year
Key Metrics to Watch
- Stockholders' equity trajectory and debt reduction plan to return to positive equity position
- Revenue growth sustainability and gross margin trends as company scales
- Free cash flow generation capability and deployment strategy to strengthen balance sheet
- Operating leverage and net margin sustainability at current profitability levels
- Insider transaction patterns and management commentary on balance sheet restoration
- Revenue growth durability and net margin retention
- Cash balance relative to liabilities and ongoing free cash flow generation
Biocryst Pharmaceuticals Inc. (BCRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 39.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.06x current ratio provides a solid financial cushion.
BCRX Profit Margin, ROE & Profitability Analysis
BCRX vs Healthcare Sector: How Biocryst Pharmaceuticals Inc. Compares
How Biocryst Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biocryst Pharmaceuticals Inc. Stock Overvalued? BCRX Valuation Analysis 2026
Based on fundamental analysis, Biocryst Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biocryst Pharmaceuticals Inc. Balance Sheet: BCRX Debt, Cash & Liquidity
BCRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biocryst Pharmaceuticals Inc.'s revenue has grown significantly by 457% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.18 indicates the company is currently unprofitable.
BCRX Revenue Growth, EPS Growth & YoY Performance
BCRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $117.1M | $32.0K | $0.06 |
| Q2 2025 | $109.3M | $32.0K | $0.02 |
| Q1 2025 | $92.8M | $32.0K | $0.00 |
| Q3 2024 | $86.7M | -$12.7M | $-0.07 |
| Q2 2024 | $82.5M | -$12.7M | $-0.06 |
| Q1 2024 | $68.8M | -$35.4M | $-0.17 |
| Q3 2023 | $75.8M | -$36.1M | $-0.19 |
| Q2 2023 | $65.5M | -$53.3M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biocryst Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
BCRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biocryst Pharmaceuticals Inc. (CIK: 0000882796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCRX
What is the AI rating for BCRX?
Biocryst Pharmaceuticals Inc. (BCRX) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCRX's key strengths?
Claude: Exceptional revenue growth of 94.1% year-over-year indicating strong market demand. Impressive net income growth of 396.9% with net margin of 30.2% showing operational leverage. ChatGPT: Revenue growth is exceptionally strong at 94.1% YoY, indicating major commercial momentum. Profitability has improved meaningfully, with 39.0% operating margin and 30.2% net margin.
What are the risks of investing in BCRX?
Claude: Critical balance sheet weakness with negative stockholders' equity of -$119.2M indicating liabilities exceed assets by $119.2M. Total liabilities of $633.3M exceed total assets of $514.2M, creating solvency concerns. ChatGPT: Stockholders equity is negative, which signals accumulated balance sheet strain despite current profitability. Total liabilities exceed total assets, limiting financial flexibility if operating performance weakens.
What is BCRX's revenue and growth?
Biocryst Pharmaceuticals Inc. reported revenue of $874.8M.
Does BCRX pay dividends?
Biocryst Pharmaceuticals Inc. does not currently pay dividends.
Where can I find BCRX SEC filings?
Official SEC filings for Biocryst Pharmaceuticals Inc. (CIK: 0000882796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCRX's EPS?
Biocryst Pharmaceuticals Inc. has a diluted EPS of $1.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BCRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biocryst Pharmaceuticals Inc. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BCRX stock overvalued or undervalued?
Valuation metrics for BCRX: ROE of N/A (sector avg: 15%), net margin of 30.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BCRX stock in 2026?
Our dual AI analysis gives Biocryst Pharmaceuticals Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BCRX's free cash flow?
Biocryst Pharmaceuticals Inc.'s operating cash flow is $347.4M, with capital expenditures of $2.5M. FCF margin is 39.4%.
How does BCRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 30.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.06 (avg: 2).